Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
197.59
-0.62 (-0.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?
August 09, 2023
Lilly shares surged 15% in one day to a record high. Here's what you should know.
Via
Investor's Business Daily
Looking Into Biogen's Recent Short Interest
August 08, 2023
Via
Benzinga
Is Sage Therapeutics a Contrarian Buy?
August 08, 2023
A regulatory setback weighed heavily on the drugmaker's shares Monday.
Via
The Motley Fool
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
August 08, 2023
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market...
Via
Benzinga
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
August 07, 2023
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter
Via
Benzinga
Biogen Unusual Options Activity For August 02
August 02, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
July 31, 2023
Via
Benzinga
Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals
July 28, 2023
Via
Benzinga
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
July 27, 2023
Biogen shares have stagnated in recent years, but the company has a plan to change that.
Via
The Motley Fool
Dow Rises Over 300 Points To Start The Week
August 07, 2023
The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses.
Via
Talk Markets
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
August 07, 2023
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.
Via
Benzinga
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
August 07, 2023
Benzinga
Via
Benzinga
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug
August 07, 2023
The company gained approval for the first oral treatment for postpartum depression.
Via
Investor's Business Daily
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
August 07, 2023
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with
Via
Benzinga
3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now
August 02, 2023
Biotech stocks can be a lucrative investment opportunity, these three biotech stocks to buy now are among analyst favorites.
Via
InvestorPlace
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
August 01, 2023
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now.
Via
InvestorPlace
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
August 01, 2023
Biogen also recently announced a plan to cut costs and focus investment on high-growth areas.
Via
The Motley Fool
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
July 31, 2023
By 2024, their medicines will likely be competing on the market, and one might win.
Via
The Motley Fool
Could This Stock Be the Next Biotech Buyout?
July 31, 2023
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next.
Via
The Motley Fool
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
July 31, 2023
Via
Benzinga
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
July 30, 2023
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits.
Via
InvestorPlace
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
July 29, 2023
There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today.
Via
InvestorPlace
Stock Market Rallies Amid Huge Earnings, Fed Rate Hike, Inflation Data: Weekly Review
July 28, 2023
Despite Thursday's downside reversal, the major indexes had a solid advance.
Via
Investor's Business Daily
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
July 28, 2023
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of
Via
Benzinga
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
July 28, 2023
Reata Pharmaceuticals (RETA) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (BIIB).
Via
InvestorPlace
Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals
July 28, 2023
Reata stock surged more than 50% on the news.
Via
Investor's Business Daily
Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B
July 28, 2023
Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of
Via
Benzinga
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
July 27, 2023
--News Direct--
Via
News Direct
Exposures
Product Safety
Why Sage Therapeutics Stock Is Tumbling Today
July 26, 2023
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.